Solid Biosciences LLC (SLDB)

Currency in USD
7.000
+0.320(+4.79%)
Closed·
After Hours
6.980-0.020(-0.29%)
·
SLDB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SLDB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.4707.000
52 wk Range
2.41010.370
Key Statistics
Prev. Close
6.68
Open
6.7
Day's Range
6.47-7
52 wk Range
2.41-10.37
Volume
1.52M
Average Volume (3m)
1.77M
1-Year Change
-22.65%
Book Value / Share
3.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SLDB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.833
Upside
+126.19%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Solid Biosciences LLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Solid Biosciences LLC Company Profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Solid Biosciences LLC SWOT Analysis


Gene Therapy Promise
Explore Solid Biosciences' SGT-003, a potential game-changer for Duchenne muscular dystrophy, showing robust microdystrophin expression and favorable safety profile
Financial Fortitude
Discover how Solid Biosciences extended its cash runway into 2027, bolstering its position with a $307 million balance and strategic cost management
Competitive Edge
Learn about Solid's proprietary capsid technology, potentially outperforming rivals like Sarepta and Pfizer in muscle targeting and reduced liver tropism
Market Potential
Analyst price targets range from $14 to $20, reflecting optimism about SGT-003's peak sales potential of $2.5-3 billion in the U.S. DMD market
Read full SWOT analysis

Compare SLDB to Peers and Sector

Metrics to compare
SLDB
Peers
Sector
Relationship
P/E Ratio
−3.9x−3.6x−0.5x
PEG Ratio
−0.180.060.00
Price/Book
1.8x2.0x2.6x
Price / LTM Sales
-4.0x3.2x
Upside (Analyst Target)
131.3%83.4%41.7%
Fair Value Upside
Unlock8.4%6.1%Unlock

Analyst Ratings

13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 15.833
(+126.19% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.59 / -0.60
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SLDB Income Statement

People Also Watch

11.93
SRPT
-7.38%
272.88
AVAV
+0.62%
51.670
SMR
+1.25%
7.390
BBAI
-5.26%
8.200
AMPX
-1.09%

FAQ

What Stock Exchange Does Solid Biosciences Trade On?

Solid Biosciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Solid Biosciences?

The stock symbol for Solid Biosciences is "SLDB."

What Is the Solid Biosciences Market Cap?

As of today, Solid Biosciences market cap is 542.61M.

What Is Solid Biosciences's Earnings Per Share (TTM)?

The Solid Biosciences EPS (TTM) is -2.92.

From a Technical Analysis Perspective, Is SLDB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Solid Biosciences Stock Split?

Solid Biosciences has split 1 times.

How Many Employees Does Solid Biosciences Have?

Solid Biosciences has 100 employees.

What is the current trading status of Solid Biosciences (SLDB)?

As of 26 Jul 2025, Solid Biosciences (SLDB) is trading at a price of 7.00, with a previous close of 6.68. The stock has fluctuated within a day range of 6.47 to 7.00, while its 52-week range spans from 2.41 to 10.37.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.